|
Mar 14
|
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
|
|
Feb 24
|
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
|
|
Feb 24
|
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
|
|
Feb 24
|
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
|
|
Feb 23
|
Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
|
|
Feb 22
|
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 21
|
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
|
|
Feb 19
|
Sanofi moves closer to selling controlling stake in $17bn-valued Opella
|
|
Feb 19
|
Challenges mount for vaccine makers
|
|
Feb 19
|
Press Release: Sanofi and CD&R sign Opella share purchase agreement
|
|
Feb 18
|
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
|
|
Feb 18
|
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
|
|
Feb 18
|
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
|
|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 14
|
Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell
|
|
Feb 13
|
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
|
|
Feb 13
|
J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
|
|
Feb 13
|
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
|
|
Feb 13
|
Sanofi to take $250M charge on study failure for E. coli vaccine
|